Etanercept biosimilar - PROBIOMED

Drug Profile

Etanercept biosimilar - PROBIOMED

Alternative Names: Infinitam

Latest Information Update: 02 Mar 2016

Price : $50

At a glance

  • Originator PROBIOMED
  • Class Antirheumatics; Disease-modifying antirheumatics; Recombinant fusion proteins
  • Mechanism of Action Immunomodulators; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Rheumatoid arthritis

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 15 Jun 2013 Phase-III clinical trials in Rheumatoid arthritis in Mexico (SC)
  • 15 Jun 2013 Adverse events and efficacy data from a phase III trial in Rhematoid arthritis presented at the 14th Annual Congress of the European League Against Rheumatism (EULAR-2013)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top